Janssen filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.
Johnson & Johnson’s Janssen unit filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.
Janssen Sues Amgen Over Ustekinumab Biosimilar
Janssen, a division of Johnson & Johnson (J&J), sued Amgen over its ustekinumab biosimilar referencing Stelara, claiming that Amgen’s intention to market the drug for rheumatic and gastrointestinal conditions infringes 2 of Janssen’s patents for the originator, according to a report from Reuters.
Stelara accumulated $9.1 billion in 2021, which represented about 18% of Janssen’s total annual revenue ($52 billion). Sales for the first 9 months of 2022 generated $7.3 billion for the company, up 7.9% from the same timeframe the previous year. Ustekinumab is used to treat Crohn disease, psoriasis, psoriatic arthritis, and ulcerative colitis.
J&J informed the court that Amgen’s filing indicates that the FDA will approve its biosimilar in the second for third quarter of 2023. Amgen is planning to launch the drug as early as next May.
The court filing could signal a pay-for-delay scheme in the ustekinumab space, a common move in the pharmaceutical industry, where a biosimilar manufacturer may pay to settle a patent infringement case in exchange for biosimilar launch postponement. This is the reasoning behind why adalimumab biosimilars are not allowed to enter the US market until 2023 despite being on the European and Canadian markets for several years.
Express Scripts to Cover Adalimumab Biosimilars
Following in the footsteps of OptumRx, Cigna’s pharmacy benefit manager (PBM) Express Scripts announced that it will add multiple adalimumab biosimilars to it formulary list at parity with the originator (Humira), according to Forbes.
Humira generates over $20 billion annually for drugmaker AbbVie, and come 2023, up to 10 adalimumab biosimilars will enter the US market: 1 in January followed by at least 7 in July. For years, stakeholders have wondered whether payers and PBMs were going to enact policies that would cover adalimumab biosimilars and how that coverage would compare with the originator.
“This decision helps us achieve lower costs for patients and plans while giving patients and providers choice and flexibility as additional biosimilars come to market…. Lack of competition allows sky-high prescription drug prices. We can generate more competition in the inflammatory drug class by adding biosimilars to our largest formularies in the coming months and…lower the costs of medications for the millions of people we serve,” said Harold Carter, chief pharma trade relations officer for Express Scripts.
Express Scripts did not disclose how many or which adalimumab biosimilars will be added to the formulary.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.